MedTrace Logo

A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

NCT06881264 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 401

Last updated 2026-01-27

No results posted yet for this study

Summary

The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Conditions

  • Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs

Interventions

DRUG

HR17031 injection

HR17031 injection

DRUG

insulin glargine

insulin glargine

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2025-09-19
Completion
2025-09-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06881264 on ClinicalTrials.gov